apnea

APNEA ((2R,3R,4S,5R)-2-[6-[2-(4-aminophenyl)ethylamino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol) is a non-selective agonist of adenosine A3 receptor.

AD109 is composed of the selective norepinephrine reuptake inhibitor Atomoxetine and the antimuscarinic agent Aroxybutynin. It demonstrates significant oral bioactivity and effectively reduces the apnea-hypopnea index (AHI).

Doxapram (hydrochloride) is a respiratory stimulant. It inhibits the function of TASK tandem pore (K2P) potassium channels, with EC50 values of 410 nM for TASK-1 and 37 nM for TASK-3. The compound displays an EC50 of 9 μM in inhibiting TASK-1/TASK-3 heterodimer channel function. Doxapram (hydrochloride) can be used in research on apnea in premature infants.

Doxapram (Dopram) is a respiratory stimulant that inhibits TASK-1, TASK-3, and TASK-1/TASK-3 heterodimer channels and is used to study ventilatory failure caused by apnea of ​​prematurity and exacerbation of chronic obstructive pulmonary disease.